Our Science
Building a global leading
synthetic lethality product pipeline
Our Science


The latest data show that cancer has become the second leading cause of death in the world causing 10 million people’s death each year globally. There are huge unmet medical needs for cancer treatment. Since foundation in 2009, IMPACT Therapeutics has been dedicated to the discovery and development of novel anti-cancer therapeutics with global rights, building a global leading synthetic lethality product pipeline to address unmet medical needs and make an impact on cancer treatment.

Synthetic Lethality

Genomic instability is one of the hallmarks of cancer cells, and the resultant mutations render cancer cells more dependent on alternative pathways for survival and proliferation, so these cancer cells are more vulnerable to targeted perturbations on those alternative pathways – a phenomenon known as synthetic lethality.


Synthetic lethality is an especially attractive and effective approach to targeting some common oncogenes that have been traditionally considered as undruggable. Synthetic lethality also has the potential to overcome the therapeutic resistance caused by new mutations that often occur with the treatment of conventional targeted therapies. Furthermore, therapies addressing synthetic lethality targets can have anti-tumor effects that are complementary to or synergistic with therapeutics employing other mechanisms. Synthetic lethality can be exploited as a drug development approach to selectively target cancer cells with certain mutations, for example, deficiencies in DNA damage response (DDR), and we see this approach usher in a new paradigm for targeted anti-cancer therapy.

Based on DDR independent research and development platform, multi-target comprehensive layout





IND filing

Ph I



01Backbone asset
  • PARP
  • Ovarian cancer(Study FLAMES,1L maintenance)

  • Ovarian cancer(Study SABRINA, 3L+BRCAm)

  • Small cell lung cancer (combo)


Senaparib is a novel PARP inhibitor, which has completed phase I clinical study in Australia and China and has met its primary endpoint. for advanced ovarian cancer maintenance treatment following first-line therapy with pre-defined efficacy boundary,and its NDA has been accepted by the National Medical Products Administration (NMPA). In August 2022, the fixed dose combination capsules of Senaparib and temozolomide for the treatment of adult patients with small cell lung cancer was granted orphan-drug designation by the U.S. Food and Drug Administration. The phase 1 dose‐escalation study of Senaparib in Australian patients with advanced solid tumors has been published in《Cancer》(doi.org/10.1002/cncr.34662). Senaparib’s phase I clinical results including safety, tolerability, and pharmacokinetics in Chinese patients with advanced solid tumors has been published in 《The Oncologist》 (doi.org/10.1093/oncolo/oyad163).

02Deep DDR pipeline
  • WEE1

IMP7068, Wee1 inhibitor, is in Phase I clinical development. In preclinical studies, IMP7068 exhibited satisfied safety, tolerability, and pharmacokinetic profiles in animal models. Additionally, IMP7068 has demonstrated in vitro and in vivo anti-cancer activities in a broad range of solid tumor cell lines and xenograft models.

  • ATR

ATR inhibitor IMP9064 has received the IND clearance from the U.S. FDA for the Phase I/II clinical study.

  • PARP1 Selective
  • ATM
  • USP1
  • Chk1/2
  • DNA-PK
03Novel SL target
  • Novel SL target
  • Hedgehog
  • Global clinical trial

  • China clinical trial

  • Pivotal study

Mutual achievement with professional attitude

To leverage financial, clinical and commercial resources required for the development and eventual sales of IMP4297(senaparib) in China, we have established a joint venture with Junshi Biosciences to develop and commercialize senaparib in China.


We intend to continue exploring partnerships through strategic collaborations including licensing arrangements, co-development and co-commercialization arrangements to maximize the clinical and commercial value of our drug candidates.